Group 1F: HER2+ Breast Cancer; Triple Positive Breast Cancer; Clinical Trials; Treatment Resistance

Name: Group 1F: HER2+ Breast Cancer; Triple Positive Breast Cancer; Clinical Trials; Treatment Resistance
Start: 2023-12-14
End: 2023-12-14

Poster #PS09-08: Genomic characterization of endocrine resistance in ER+HER2+ breast cancers in the POETIC Trial.

Poster #PO2-04-06: Investigation of the genomic evolution of HER2-positive breast cancer following progression on dual HER2-targeted therapy with trastuzumab and tucatinib.

+ Add to Google Calendar
+ iCal / Outlook export

Date

Dec 14 2023

Time

10:00 am - 11:30 am

Group 1F: HER2+ Breast Cancer; Triple Positive Breast Cancer; Clinical Trials; Treatment Resistance

Date

Time

Zoom Webinar